These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 32854430)

  • 1. Targeting the sAC-Dependent cAMP Pool to Prevent SARS-Cov-2 Infection.
    Aslam M; Ladilov Y
    Cells; 2020 Aug; 9(9):. PubMed ID: 32854430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Discovery Strategies for SARS-CoV-2.
    Shyr ZA; Gorshkov K; Chen CZ; Zheng W
    J Pharmacol Exp Ther; 2020 Oct; 375(1):127-138. PubMed ID: 32723801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19.
    Yang N; Shen HM
    Int J Biol Sci; 2020; 16(10):1724-1731. PubMed ID: 32226290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.
    Abu-Farha M; Thanaraj TA; Qaddoumi MG; Hashem A; Abubaker J; Al-Mulla F
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32429572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
    Patil AM; Göthert JR; Khairnar V
    Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications.
    Ballout RA; Sviridov D; Bukrinsky MI; Remaley AT
    FASEB J; 2020 Jun; 34(6):7253-7264. PubMed ID: 32367579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2.
    Sauvat A; Ciccosanti F; Colavita F; Di Rienzo M; Castilletti C; Capobianchi MR; Kepp O; Zitvogel L; Fimia GM; Piacentini M; Kroemer G
    Cell Death Dis; 2020 Aug; 11(8):656. PubMed ID: 32814759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [SARS-CoV-2 protease: an excellent target to develop drugs against COVID-19].
    Ladoux A; Azoulay S; Dani C
    Med Sci (Paris); 2020; 36(6-7):555-558. PubMed ID: 32558640
    [No Abstract]   [Full Text] [Related]  

  • 10. SARS-CoV-2 RNA polymerase as target for antiviral therapy.
    Buonaguro L; Tagliamonte M; Tornesello ML; Buonaguro FM
    J Transl Med; 2020 May; 18(1):185. PubMed ID: 32370758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LY6E Restricts Entry of Human Coronaviruses, Including Currently Pandemic SARS-CoV-2.
    Zhao X; Zheng S; Chen D; Zheng M; Li X; Li G; Lin H; Chang J; Zeng H; Guo JT
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32641482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. α-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19.
    Williams SJ; Goddard-Borger ED
    Biochem Soc Trans; 2020 Jun; 48(3):1287-1295. PubMed ID: 32510142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection.
    Clementi N; Ferrarese R; Criscuolo E; Diotti RA; Castelli M; Scagnolari C; Burioni R; Antonelli G; Clementi M; Mancini N
    J Infect Dis; 2020 Aug; 222(5):722-725. PubMed ID: 32559285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
    Zhu Y; Yu D; Yan H; Chong H; He Y
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cationic drugs and COVID-19.
    Brenna OV; Torretta S; Pignataro L; Di Berardino F
    Int J Immunopathol Pharmacol; 2020; 34():2058738420966078. PubMed ID: 33045858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vimentin as a target for the treatment of COVID-19.
    Li Z; Paulin D; Lacolley P; Coletti D; Agbulut O
    BMJ Open Respir Res; 2020 Sep; 7(1):. PubMed ID: 32913008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Novel Insight of SARS-CoV-2 Molecular Biology and Pathogenesis and Therapeutic Options.
    Asghari A; Naseri M; Safari H; Saboory E; Parsamanesh N
    DNA Cell Biol; 2020 Oct; 39(10):1741-1753. PubMed ID: 32716648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells.
    Baig MS; Alagumuthu M; Rajpoot S; Saqib U
    Drugs R D; 2020 Sep; 20(3):161-169. PubMed ID: 32592145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct SARS-CoV-2 infection of the heart potentiates the cardiovascular sequelae of COVID-19.
    Bose RJC; McCarthy JR
    Drug Discov Today; 2020 Sep; 25(9):1559-1560. PubMed ID: 32592868
    [No Abstract]   [Full Text] [Related]  

  • 20. COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks.
    Blaess M; Kaiser L; Sauer M; Csuk R; Deigner HP
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32668803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.